The financial crisis poses serious challenges to all industries, especially to broker-dealers who face a drastically changed marketplace and increased regulatory scrutiny. Despite these struggles, there may be opportunities for broker-dealers to emerge from and move forward in the economic crisis.
This Foley Executive Briefing Series program focused on strategies for enduring the financial crisis and adapting new business models needed for the uncertain future ahead.
Topics included:
- Industry trends, opportunities, and risks
- Merger and acquisition considerations and strategies
- FINRA enforcement issues and guidance
- Regulatory developments for financial services companies
Speakers
- Edwin D. Mason
Foley Partner, Transactional & Securities and Private Equity & Venture Capital Practices
- Richard G. Wallace
Foley Partner, Securities Enforcement & Litigation Practice, and Former Vice President and Chief Counsel, FINRA Market Regulation Department
Moderators
- Martin A. Traber
Foley Partner, Private Equity & Venture Capital and Transactional & Securities Practices
- William E. Davis
Managing Partner, Foley’s Miami office, and Partner, General Commercial Litigation and Intellectual Property Litigation Practices
To learn more about this program, please contact Elie Harris at [email protected].
Strategies for Broker-Dealers: Moving Forward During Economic Difficulty is part of the Foley Executive Briefing Series.
People
Related Insights
30 August 2024
Viewpoints
FTC’s Ban on Noncompete Agreements Is Blocked
04 September 2024
Events
Navigating Intellectual Property While Building with AI
Foley Partner Eric Sophir will present on the topic of “Navigating Intellectual Property while building with AI” at the Martin Luther King Jr. Memorial Library on Wednesday, September 4, 2024, from 4:00 p.m.-5:00 p.m. EDT.
29 August 2024
Manufacturing Industry Advisor
2024 CPSC and FDA Enforcement Trends
The enforcement trends of 2023 have continued into 2024, especially with respect to the U.S. Consumer Product Safety Commission and the U.S. Food and Drug Administration.